Danaher Corporation
DHR
$200.53
-2.11%
Danaher Corporation is a global science and technology innovator, primarily manufacturing scientific instruments, consumables, and diagnostic solutions for the life sciences and diagnostics industries. As a market leader in the healthcare technology sector, Danaher is known for its robust portfolio of well-known brands and its proven ability to execute strategic acquisitions and divestitures, such as the recent spin-off of Veralto. The current investor narrative centers on the company's recovery from a post-pandemic slowdown, with recent news highlighting its acquisition of Masimo and debates over whether its stock, down from its peak, presents a buying opportunity. Investors are closely watching the pace of growth in its bioprocessing and diagnostics segments, as well as the integration of new acquisitions, to gauge the sustainability of its earnings momentum.…
DHR
Danaher Corporation
$200.53
Related headlines
Investment Opinion: Should I buy DHR Today?
Based on the data, DHR is rated a Buy. The consensus is Strong Buy with an average target of $228.83, implying ~10% upside. The thesis is that Danaher's high-quality recurring revenue, improving growth, and strategic acquisitions will drive earnings recovery, justifying the forward PE of 22.3x.
Sign up to view all
DHR 12-Month Price Forecast
The AI assessment leans bullish, driven by the strong analyst consensus, improving revenue trends, and a reasonable forward valuation. However, confidence is medium due to the stock's underperformance and operational volatility. The key is whether the earnings recovery materializes as expected. If Q2 2026 shows accelerating growth and Masimo integration progresses, the stance would be upgraded to high confidence. Conversely, any negative surprise in bioprocessing or the acquisition could flip the stance to neutral or bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Danaher Corporation's 12-month outlook, with a consensus price target around $229.09 and implied upside of +14.2% versus the current price.
Average Target
$229.09
0 analysts
Implied Upside
+14.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$195 - $310
Analyst target range
Danaher is covered by 23 analysts, with a consensus recommendation of 'Strong Buy' and a mean rating of 1.5 (where 1 is Strong Buy and 5 is Sell). The average price target is $228.83, implying an upside of approximately 10.2% from the current price of $207.66. The distribution of ratings is heavily skewed towards the bullish side, with no Sell ratings, reflecting strong confidence in the company's growth prospects. Recent actions from firms like Evercore ISI (Outperform) and HSBC (Buy) reinforce this positive sentiment, although Citigroup's downgrade to Neutral in May 2026 introduces a note of caution.
Drowning in data?
Find the real signal!
Bulls vs Bears: DHR Investment Factors
Danaher presents a balanced but slightly bullish case. The bull case is anchored by a Strong Buy analyst consensus, a high-quality recurring revenue base (84.5% of sales), and a clear growth catalyst in the Masimo acquisition. The bear case highlights significant underperformance versus the S&P 500, a high trailing PE that implies aggressive earnings expectations, and recent operational volatility. The most important tension is whether the expected earnings recovery—implied by the gap between trailing (45.2x) and forward (22.3x) PEs—materializes as quickly as analysts forecast. If bioprocessing continues to recover and Masimo integrates smoothly, the stock likely re-rates higher; if growth disappoints, the premium valuation could compress sharply. Currently, the weight of evidence (analyst targets, improving revenue trends, strong margins) slightly favors the bulls, but the stock's recent price action warrants caution.
Bullish
- Strong Buy Consensus with 10% Upside: 23 analysts rate DHR a Strong Buy (mean 1.5), with an average price target of $228.83, implying ~10.2% upside from $207.66. No Sell ratings and recent upgrades from Evercore ISI and HSBC reinforce positive sentiment.
- High-Quality Recurring Revenue Base: In Q1 2026, recurring revenue accounted for $5.031B of $5.951B total revenue (84.5%), providing stability and predictability. This recurring stream supports consistent cash flows and reduces earnings volatility.
- Improving Revenue Growth Trajectory: Q1 2026 revenue grew 3.7% YoY to $5.951B, following sequential increases from $5.936B in Q2 2025 to $6.838B in Q4 2025. The steady recovery from post-pandemic destocking indicates a positive trend.
- Masimo Acquisition Adds Growth Catalyst: The acquisition of Masimo, expected to close, provides a new revenue stream and cross-selling opportunities in diagnostics. Analysts view it as financially solid, with conservative growth projections that still enhance DHR's portfolio.
Bearish
- Underperformance vs. S&P 500: DHR's 1-year return is +4.3% vs. S&P 500's +18.7%, a relative underperformance of -14.3 percentage points. YTD, DHR is down -9.9% while the S&P is up +12.9%, indicating persistent investor skepticism.
- High Trailing PE Suggests Earnings Risk: Trailing PE is 45.2x, well above the forward PE of 22.3x, implying the market expects a massive earnings jump. If earnings recovery stalls, the stock could face multiple compression.
- Recent Volatility and Sharp Drops: In July 2026, the stock fell ~12% in a week due to shipment delays in biotech, and in May 2026 it dropped to $161.91, near the 52-week low. Such swings highlight operational and sentiment fragility.
- Modest Growth May Not Justify Premium: Revenue growth of 3.7% YoY is modest for a company trading at 6.6x sales and 22.3x forward earnings. If growth doesn't accelerate, the valuation could be seen as stretched.
DHR Technical Analysis
Danaher's stock has been in a broad recovery phase over the past year, with a 1-year price change of +4.3%, though it has significantly underperformed the S&P 500's +18.7% gain. The current price of $207.66 sits at 62% of its 52-week range (low: $160.93, high: $242.80), indicating the stock is in the lower-middle portion of its range, suggesting it is neither near highs nor at extreme lows. This positioning implies that while the stock has recovered from its lows, it still has substantial upside to reach its previous peak, but it also reflects lingering investor caution.
Beta
0.81
0.81x market volatility
Max Drawdown
-33.1%
Largest decline past year
52-Week Range
$161-$243
Price range past year
Annual Return
+4.1%
Cumulative gain past year
| Period | DHR Return | S&P 500 |
|---|---|---|
| 1m | -3.3% | -1.6% |
| 3m | +11.3% | +2.2% |
| 6m | +7.1% | +14.4% |
| 1y | +4.1% | +16.2% |
| ytd | -13.0% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DHR Fundamental Analysis
Danaher's revenue trajectory shows a modest recovery, with the most recent quarter (Q1 2026) reporting revenue of $5.951 billion, a 3.7% year-over-year increase. This growth follows a pattern of sequential improvement, as Q4 2025 revenue was $6.838 billion, up from $5.936 billion in Q2 2025, indicating a steady but slow recovery. The company's growth is being driven by its recurring revenue streams, which accounted for $5.031 billion of the $5.951 billion in Q1 2026, highlighting the stability of its consumables and services businesses. However, the overall growth rate remains modest, suggesting that the bioprocessing segment is still recovering from the post-pandemic destocking, and the recent acquisition of Masimo is expected to provide an additional growth catalyst.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+3.7%
YoY Comparison
Gross Margin
60.3%
Latest Quarter
Free Cash Flow
$5.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DHR Overvalued?
Given Danaher's positive net income, the PE ratio is the most appropriate valuation metric. The trailing PE stands at 45.2x, while the forward PE is 22.3x, indicating that the market expects significant earnings growth in the coming year. This wide gap between trailing and forward multiples suggests that analysts anticipate a substantial recovery in profitability, likely driven by margin expansion and the integration of Masimo. The forward PE of 22.3x is more in line with the company's historical average, implying that the market is pricing in a normalization of earnings rather than a permanent slowdown.
PE
45.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but notable. Danaher carries a manageable debt-to-equity ratio of 0.35, and its current ratio of 1.87 indicates ample liquidity. However, the company's earnings are sensitive to the pace of recovery in bioprocessing; Q2 2025 net income was only $555M (EPS $0.77) due to one-time charges, showing volatility. The high trailing PE of 45.2x means that any earnings miss could trigger a sharp de-rating. Additionally, free cash flow of $5.29B TTM is strong, but the company's aggressive M&A strategy (e.g., Masimo) could strain balance sheet if debt increases. Revenue concentration in life sciences and diagnostics exposes it to sector-specific downturns, as seen in the post-pandemic destocking that caused revenue declines in 2023-2024.
